(2-methoxy-ethoxy)-acetone | 88986-89-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-methoxy-ethoxy)-acetone
• 英文别名: (2-Methoxy-aethoxy)-aceton；1-(2-Methoxyethoxy)propan-2-one
• CAS: 88986-89-4
• 化学式: C₆H₁₂O₃
• mdl: MFCD01105045
• 分子量: 132.159
• InChiKey: MSYGEAQDQJEOCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2914509090

反应信息

• 作为产物：
  描述：

  3-(2-methoxyethoxy)prop-1-yne 以37%的产率得到
  参考文献：
  名称：

  MATIESHKA, A. I.;MOZOLIS, V. V., TR. AN LITSSR, 1986, N 2/153, 41-48

  摘要：

  DOI：

文献信息

• QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS
  申请人：Wilson Dean

  公开号：US20080167305A1

  公开（公告）日：2008-07-10

  The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及作为电压门控钠通道抑制剂有用的化合物。该发明还提供了包括本发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。
• Methylphenidate-Prodrugs, Processes of Making and Using the Same
  申请人：KemPharm, Inc.

  公开号：US20150266911A1

  公开（公告）日：2015-09-24

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  目前的技术是针对前药和组合物的，用于治疗包括甲基苯丙胺或甲基苯丙胺衍生物的至少与醇、胺、羧酸、硫醇或其衍生物结合的各种疾病和/或紊乱。在某些实施例中，这些结合物还包括至少一个连接剂。该技术还涉及合成甲基苯丙胺或甲基苯丙胺衍生物，结合至少一个醇、胺、羧酸、硫醇或其衍生物或其组合的方法。
• [EN] SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS<br/>[FR] DÉRIVÉS DE SPIRO 1,3,4-THIADIAZOLINE INHIBITEURS DE KSP
  申请人：SCHERING CORP

  公开号：WO2010132520A1

  公开（公告）日：2010-11-18

  The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.

  本发明涉及下式（I）的化合物（其中X、R1、R2、R3、p、环A和环B的定义如本文所述）。本发明还涉及包括这些化合物的组合物（包括药用组合物），单独或与一个或多个额外治疗剂结合使用的方法，以及用于抑制KSP肌动蛋白活性和治疗与KSP肌动蛋白活性相关的细胞增殖性疾病或疾病的方法。
• HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS
  申请人：THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  公开号：US20160168140A1

  公开（公告）日：2016-06-16

  The invention relates to heterocyclic compounds and their use as antibiotics and/or as antibiotic potentiators. The compounds may act as colistin potentiators and SOS inhibitors.

  这项发明涉及杂环化合物及其作为抗生素和/或抗生素增效剂的用途。这些化合物可能作为科利斯汀增效剂和SOS抑制剂起作用。
• Pyrrolopyridine kinase inhibiting compounds
  申请人：Dong Han-Qing

  公开号：US20070129364A1

  公开（公告）日：2007-06-07

  Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

  由式（I）表示的化合物或其立体异构体或其药用可接受的盐，是对动物中至少一种Abl、Aurora-A、Blk、c-Raf、cSRC、Src、PRK2、FGFR3、Flt3、Lck、Mek1、PDK-1、GSK3β、EGFR、p70S6K、BMX、SGK、CaMKII、Tie-2、IGF-1R、Ron、Met和KDR激酶的抑制剂，包括人类，用于治疗和/或预防癌症等各种疾病和病况。